Stayble has now enrolled and treated the first patient in the company's clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease. The company's CEO Andreas Gerward shared his thoughts on the milestone in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/stayble-enrols-the-first-patient-in-herniated-disc-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-enrols-the-first-patient-in-herniated-disc-study,c3829106

(c) 2023 Cision. All rights reserved., source Press Releases - English